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Yamanaka and colleagues, in a Science article currently published online, have generated induced pluripo-
tent stem (iPS) cells from liver and stomach cells, suggesting that transcription factor-induced reprogram-
ming is not restricted to particular cell types (Aoi et al., 2008). These results also provide important insight
into the mechanistic basis of reprogramming.The reprogramming of somatic cells into
induced pluripotent stem (iPS) cells was
a breakthrough discovery of 2006 (Taka-
hashi and Yamanaka, 2006). Yamanaka
and colleagues showed that murine fibro-
blast populations can be reprogrammed
by overexpressing four transcription fac-
tors: Oct4, Sox2, Klf4, and c-Myc. Fibro-
blast-derived iPS cells are molecularly
and functionally indistinguishable from
embryonic stem (ES) cells (Maherali et al.,
2007; Okita et al., 2007; Wernig et al.,
2007). The same approach has since been
shown to work with human fibroblasts
(Takahashi et al., 2007; Yu et al., 2007),
providing an elegant method to obtain
human ES-like, pluripotent populations
that hold great promise for the study and
treatment of human diseases.
Although reprogramming fibroblasts to
an ES-like state is now clearly feasible,
typically only one in a thousand recipient
cells is reprogrammed. Several explana-
tions may account for this low efficiency
(Figure 1). The integration of retro- or len-
tiviruses used to deliver the four factors
may fortuitously modify the expression
of an essential, unknown factor in a small
subset of cells. Alternatively, the hetero-
geneous fibroblast population could
harbor cell types that are predisposed to
reprogramming. It is even possible that
only rare adult stem cells rather than dif-
ferentiated cells are the source of the re-
programmed cells. Can only fibroblast
cultures be reprogrammed? In their latest
study, Yamanaka and colleagues (Aoi et al.,
2008), in combination with recent papers
from the Jaenisch and Hochedlinger labs
(Brambrink et al., 2008; Stadtfeld et al.,
2008), begin to address these questionsof inefficiency, donor cell type, and the
mechanism(s) responsible for reprogram-
ming (Figure 1).
To test whether the same set of tran-
scription factors could induce reprogram-
ming of epithelial cell types, Yamanaka
and colleagues retrovirally transduced
primary murine cells from liver and stom-
ach tissues (Aoi et al., 2008). Selection
for expression of the ES cell markers
Fbx15 and Nanog 7 days after viral infec-
tion yielded iPS cells that (1) had activated
ES cell-specific transcription, (2) were de-
methylated at the endogenous Oct4 and
Nanog promoters, and (3) gave rise to
germline-competent chimeric mice, the
gold standard for demonstrating pluripo-
tency (Table 1). Thus, reprogramming is
not only restricted to cells of mesodermal
origin, such as fibroblasts, but also works
on endodermal cell types.
Of note, the kinetics of reprogramming
appears to vary when target populations
from different tissues are used. Specifi-
cally, when selection for Fbx15 expression
was applied as early as 3 days after viral
transduction, fibroblast-derived iPS cells
were only partially reset to the ES-like
state (Takahashi and Yamanaka, 2006),
whereas populations of infected liver cells
yield completely reprogrammed iPS colo-
nies when selected at this early time point
(Aoi et al., 2008) (Table 1). Why might liver
cells be reprogrammed faster than fibro-
blasts? Gene expression in epithelial cells
may be more similar to ES cells than pat-
terns observed in fibroblasts (Aoi et al.,
2008). In addition, a loss of hepatocyte-
specific gene expression is characteristic
of explanted hepatocytes (Elaut et al.,
2006). Hence these cells may be moreCell Stemamenable to induced alterations and
perhaps require fewer transcriptional
changes to reach a reprogrammed state.
Two recent papers used inducible lenti-
viruses to assess the temporal require-
ments for factor expression and defined
intermediate stages of the reprogramming
process (Brambrink et al., 2008; Stadtfeld
et al., 2008). Both groups found a gradual
activation of ES cell maker genes, includ-
ing upregulation of the stage-specific
embryonic antigen 1 (SSEA1) that pre-
ceded the increase in endogenous Nanog,
Oct4, and Sox2 expression. SSEA1-posi-
tive cells arose from a subpopulation of
cells that had lost the fibroblast surface
marker Thy1 and activated the stem cell
marker alkaline phosphatase. Importantly,
Hochedlinger’s group isolated Thy1-
negative orThy1-negative/SSEA1-positive
cells, which yielded cell populations en-
riched for precursors of fully reprog-
rammed iPS cells. In these ‘‘primed’’ sub-
populations, retrovirally encoded factors
were gradually silenced while endoge-
nous, ES cell-specific transcription took
over (Stadtfeld et al., 2008). Performing a
similar analysis during liver iPS cell forma-
tion will be a first step toward explaining
the differences in reprogramming kinetics
observed in various target populations.
Two surprising observations distin-
guish liver and stomach iPS cells from
their fibroblast-derived counterparts (Aoi
et al., 2008) (Table 1), even though the
cells appear completely reprogrammed
to the ES-like state. First, the majority of
chimeric mice generated from stomach
and liver iPS cells die postnatally, which
is not the case for fibroblast iPS chimera.
Second, while 30% of chimeric miceCell 2, April 2008 ª2008 Elsevier Inc. 295
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adult mice derived from liver or stomach
iPS cells did not. Of note, Aoi et al. (2008)
also observed that liver and stomach iPS
cells had 2- to 3-fold fewer viral integra-
tion events than fibroblast iPS cells. Thus,
epithelial iPS cells might be less likely to
have integration-induced oncogene
expression, or the reduced tumor incidence
could be due to more stable silencing
of the retroviral transgenes, especially of
transgenic c-Myc. Perinatal death, on the
other hand, might reflect differences in
genomic stability of the donor cell popula-
tion. iPS cells derived from liver or stom-
ach cells could have acquired more muta-
tions or have unbalanced imprinted gene
expression compared to fibroblasts, a
phenomena that has been an issue in
cloned animals (Yang et al., 2007). A de-
tailed analysis of the transcriptome, chro-
matin state, and ploidy of fibroblast and
epithelial cell-derived iPS cells will be re-
quired to explain these differences in iPS
cell properties.
In addition to the reduction in epithelial
iPS viral integrations, Aoi et al. failed to
detect any common retroviral integration
sites in iPS cells. This finding argues
against the model that reprogramming
depends on the activation or repression
of a specific, as yet unknown, essential
factor (Figure1). Furthermore, the Jaenisch
and Hochedlinger groups reveal that fibro-
blast reprogramming requires ectopic
transcription factor expression for only
Table 1. Properties of iPSCells Originating fromFibroblast or Epithelial Cell Populations
Timing of
iPS Selection
Fibroblast
iPS
Liver
iPS
Stomach
iPS
Reprogramming of ES cell marker
gene expression
Early (day 3) Partial Complete ND
Generation of adult chimera Early (day 3) No Yes ND
Reprogramming of ES cell-specific
transcription of marker genes
Late
(at or after day7)
Complete Complete Complete
Generation of adult chimera Late
(at or after day 7)
Yes Yes Yes
Perinatal death of chimera No Yes Yes
Tumors observed in chimera Yes No No
Number of integration
sites per virus
10–12 <4 <4
Enhancement of iPS production
by c-Myc
10-fold <2-fold ND
Figure 1. Reprogramming Is an Ordered, yet Inefficient, Process
Data presented by Aoi et al. (2008) and the Jaenisch and Hochedlinger laboratories (Brambrink et al., 2008; Stadtfeld et al., 2008) are integrated and begin to open
the ‘‘black box’’ of events that take place during somatic cell reprogramming and iPS colony generation. Some points are clarified, but questions remain.296 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.
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et al., 2008; Stadtfeld et al., 2008). To-
gether, these findings suggest that nonin-
tegrating reprogramming methods may
be developed to provide transient overex-
pression of the transcription factors, which
will positively impact the ability to translate
iPS technology into therapies.
To begin to determine the origin of the
cell that gives rise to iPS colonies, Aoi
et al. (2008) used a lineage-tracing strate-
gy that identifies cells that, at some time,
have expressed the hepatic gene albu-
min. Their results indicate that liver-de-
rived iPS cells were almost all positive
for this reporter, suggesting that lineage-
committed cells can be reprogrammed
to an ES-like state. However, although
albumin is expressed in mature hepato-
cytes and liver progenitors, it could con-
ceivably have been activated during the
reprogramming process in vitro. To con-
clusively demonstrate that iPS cells arise
from terminally differentiated cells and
not rare stem cells, populations with
differentiation-associated genomic rear-
rangements, such as lymphocytes, will
need to be examined.
Although the hypothesis that iPS cells
arise from a rare stem cell remains possi-Cancer: Inappropr
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renewal, associated with normal st
embryonic stem cell (ESC)-like gen
epithelial cancers.
Increasing evidence suggests that path-
ways and properties associated with nor-
mal stem cells are important for cancer
development. The link between genes im-
portant for normal stem cell developmentble until an unambiguously genetically
marked cell can be reprogrammed to indi-
cate the differentiation state of the donor
cell, Yamanaka’s latest studies suggest
that the low efficiency of reprogramming
is not a result of directed insertional muta-
genesis and that factor-induced reprog-
ramming is a universal process that is
not restricted to particular cell types.
Given that the overall efficiency of revert-
ing early reprogramming intermediates
into iPS cells is still low (Brambrink et al.,
2008; Stadtfeld et al., 2008), transcription
factor-induced reprogramming must re-
quire rare stochastic, likely epigenetic,
events. Analyzing subpopulations of iPS
intermediates from multiple tissues via
genome-wide approaches for factor bind-
ing and chromatin changes should reveal
important molecular events that occur
during this cascade. Such insights may
lead to safer, more efficient reprogram-
ming methods that will be necessary to
translate iPS cells into therapeutic tools.
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